Ildong Pharmaceutical Resumes Dividend of KRW 200 per Share and Returns to Profit in 2025... Strengthened Shareholder Return Policy, Maintains Transparent Governance
Consolidated revenue in 2025: KRW 566.9B, operating profit KRW 19.5B, net profit KRW 23.7B, turning from net loss of KRW 12.4B in previous year.
Declared year-end cash dividend of KRW 200 per ordinary share (total KRW 6.3B), resuming dividends after no dividend in prior year.
Adopted 'dividend amount first, record date later' policy to enhance predictability.
Largest shareholder Ildong Holdings holds 34.45%, minority shareholders 62.83%.
Board: 4 inside directors, 2 outside directors (33%), meeting legal requirements. All male composition.
Audit: one full-time and one part-time auditor, both CPAs, ensuring independence and expertise.
Decided to merge wholly-owned subsidiary Yunovia in 2026 (no dilution).
Most core governance indicators complied (4-week prior notice for AGM, electronic voting, avoidance of concentrated date).
[AI Comprehensive Analysis]This governance report reflects positive signals such as return to profit and dividend resumption, but improvement areas remain including lack of board gender diversity and absence of outside director evaluation system. Overall, the company maintains stable governance with efforts toward shareholder value enhancement.